WO1989004875A3 - Characterization and detection of sequences associated with autoimmune diseases - Google Patents

Characterization and detection of sequences associated with autoimmune diseases Download PDF

Info

Publication number
WO1989004875A3
WO1989004875A3 PCT/US1988/004067 US8804067W WO8904875A3 WO 1989004875 A3 WO1989004875 A3 WO 1989004875A3 US 8804067 W US8804067 W US 8804067W WO 8904875 A3 WO8904875 A3 WO 8904875A3
Authority
WO
WIPO (PCT)
Prior art keywords
sequences
autoimmune diseases
iddm
antibodies
dna sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1988/004067
Other languages
French (fr)
Other versions
WO1989004875A2 (en
Inventor
Henry A Erlich
Glenn T Horn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22397216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1989004875(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cetus Corp filed Critical Cetus Corp
Priority to EP89901373A priority Critical patent/EP0439458B1/en
Priority to JP1501309A priority patent/JP2877165B2/en
Priority to DE3889927T priority patent/DE3889927T2/en
Publication of WO1989004875A2 publication Critical patent/WO1989004875A2/en
Publication of WO1989004875A3 publication Critical patent/WO1989004875A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

DNA sequences and corresponding amino acid sequences from the HLA class II beta region of the human genome that are associated with insulin-dependent diabetes mellitus (IDDM) and Pemphigus vulgaris (PV) have been identified. Specifically, marker DNA sequences which detect either directly or indirectly the identity of the codon encoding for the amino acid at position 57 of the DQ-beta protein sequence are disclosed as well as sequences from the DR-beta region. These sequences may be used to generate DNA hybridization probes and antibodies for assays to detect a person's susceptibility to autoimmune diseases, such as IDDM and PV. Such antibodies and peptides encoded by said DNA sequences can be used therapeutically or prophylactically.
PCT/US1988/004067 1987-11-17 1988-11-14 Characterization and detection of sequences associated with autoimmune diseases Ceased WO1989004875A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP89901373A EP0439458B1 (en) 1987-11-17 1988-11-14 Characterization and detection of sequences associated with autoimmune diseases
JP1501309A JP2877165B2 (en) 1987-11-17 1988-11-14 Characterization and detection of sequences associated with autoimmune diseases
DE3889927T DE3889927T2 (en) 1987-11-17 1988-11-14 LABELING AND DETECTION OF SEQUENCES ASSOCIATED WITH AUTOIMMUNE DISEASES.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US121,519 1987-11-17
US07/121,519 US6194561B1 (en) 1986-03-13 1987-11-17 Characterization and detection of sequences associated with autoimmune diseases

Publications (2)

Publication Number Publication Date
WO1989004875A2 WO1989004875A2 (en) 1989-06-01
WO1989004875A3 true WO1989004875A3 (en) 1989-06-15

Family

ID=22397216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/004067 Ceased WO1989004875A2 (en) 1987-11-17 1988-11-14 Characterization and detection of sequences associated with autoimmune diseases

Country Status (7)

Country Link
US (2) US6194561B1 (en)
EP (1) EP0439458B1 (en)
JP (1) JP2877165B2 (en)
AT (1) ATE106454T1 (en)
CA (1) CA1339098C (en)
DE (1) DE3889927T2 (en)
WO (1) WO1989004875A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310893A (en) * 1986-03-31 1994-05-10 Hoffmann-La Roche Inc. Method for HLA DP typing
US5567809A (en) * 1986-03-13 1996-10-22 Hoffmann-La Roche Inc. Methods and reagents for HLA DRbeta DNA typing
US5714380A (en) * 1986-10-23 1998-02-03 Amoco Corporation Closed vessel for isolating target molecules and for performing amplification
US5192659A (en) * 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
GB9002625D0 (en) * 1990-02-06 1990-04-04 Univ Singapore Human leukocyte antigen typing
DE69121099T3 (en) * 1990-05-01 2001-01-25 The Board Of Trustees Of The Leland S. Stanford Junior University, Stanford Mixtures of substances for use in a method of treating a person suffering from multiple sclerosis
US7294712B2 (en) * 1990-06-04 2007-11-13 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
JP2560160B2 (en) * 1990-08-20 1996-12-04 社団法人北里研究所 Novel DNA nucleotide sequence and its use
AU656161B2 (en) * 1990-12-06 1995-01-27 F. Hoffmann-La Roche Ag Methods and reagents for HLA DRbeta DNA typing
DK0515660T3 (en) * 1990-12-21 1997-07-28 Hoffmann La Roche HLA-DQbeta DNA Typing
AU660306B2 (en) * 1991-02-12 1995-06-22 Roussel-Uclaf Nucleotidic sequences coding for variable regions of beta chains of human T lymphocyte receptors, corresponding peptidic segments and diagnostic and therapeutic applications
FR2679252B1 (en) * 1991-07-17 1993-12-10 Bio Merieux PROBE SYSTEM FOR HLA DR TYPING, AND TYPING METHOD USING THE SAME.
US5976789A (en) * 1991-07-17 1999-11-02 Bio Merieux System of probes enabling HLA-DR typing to be performed, and typing method using said probes
FR2684688B1 (en) * 1991-12-04 1994-03-18 Bertin Et Cie METHOD FOR SELECTING AT LEAST ONE MUTATION SCREEN, ITS APPLICATION TO A PROCESS FOR QUICK IDENTIFICATION OF POLYMORPHIC ALLELES AND DEVICE FOR ITS IMPLEMENTATION.
US5763591A (en) * 1996-03-25 1998-06-09 Cedars-Sinai Medical Center Polynucleic acid sequences that are functionally associated with the development of autoimmune disease
FR2749308B1 (en) * 1996-06-03 1998-07-24 Bio Merieux NUCLEOTIDE PROBES AND METHOD FOR DETERMINING THE HLA DQB1 TYPE
CA2281894A1 (en) * 1997-02-21 1998-08-27 Saigene Corporation Compositions and methods for determining predisposition to insulin dependent diabetes mellitus
US5985567A (en) * 1997-08-15 1999-11-16 Beckman Coulter, Inc. Hybridization detection by pretreating bound single-stranded probes
ATE283918T1 (en) 1999-04-26 2004-12-15 Chugai Pharmaceutical Co Ltd TUMOR SUPPRESSOR GENE
KR100762444B1 (en) * 1999-11-01 2007-10-04 시오자와 순이찌 Probe for Chronic Arthritis
US7820030B2 (en) * 2003-04-16 2010-10-26 Handylab, Inc. System and method for electrochemical detection of biological compounds
EP1536021A1 (en) * 2003-11-27 2005-06-01 Consortium National de Recherche en Genomique (CNRG) Method for HLA typing
US20100086914A1 (en) * 2008-10-03 2010-04-08 Roche Molecular Systems, Inc. High resolution, high throughput hla genotyping by clonal sequencing
EP2279411A4 (en) * 2008-04-09 2011-09-21 Pacific Northwest Res Inst METHODS OF SCREENING GENETIC PREDISPOSITION FOR TYPE I DIABETES
US20100261189A1 (en) * 2008-10-03 2010-10-14 Roche Molecular Systems, Inc. System and method for detection of HLA Variants

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0084796A2 (en) * 1982-01-22 1983-08-03 Cetus Corporation HLA typing method and cDNA probes used therein
WO1986007464A1 (en) * 1985-06-14 1986-12-18 Genetic Systems Corporation Methods for identifying alleles associated with increased risk of diabetes
EP0237362A1 (en) * 1986-03-13 1987-09-16 F. Hoffmann-La Roche Ag Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids and kits therefor
WO1988002783A1 (en) * 1986-10-16 1988-04-21 Nordisk Insulinlaboratorium A process and an agent for detection of gene structures in humans having a great tendency to develop iddm

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US5110920A (en) 1982-01-22 1992-05-05 Cetus Corporation HLA typing method and DNA probes used therein
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5059519A (en) 1986-07-01 1991-10-22 University Of Massachusetts Medical School Oligonucleotide probes for the determination of the proclivity for development of autoimmune diseases
US4965189A (en) 1986-07-01 1990-10-23 University Of Massachusetts Medical School Probes for the determination of the proclivity for development of autoimmune diseases
US5039606A (en) 1987-10-29 1991-08-13 Virginia Mason Research Center Diagnostic probe for diabetes type I predisposition
US4971902A (en) 1987-10-30 1990-11-20 Virginia Mason Research Center Diagnostic probe for rheumatoid arthritis predisposition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0084796A2 (en) * 1982-01-22 1983-08-03 Cetus Corporation HLA typing method and cDNA probes used therein
WO1986007464A1 (en) * 1985-06-14 1986-12-18 Genetic Systems Corporation Methods for identifying alleles associated with increased risk of diabetes
EP0237362A1 (en) * 1986-03-13 1987-09-16 F. Hoffmann-La Roche Ag Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids and kits therefor
WO1988002783A1 (en) * 1986-10-16 1988-04-21 Nordisk Insulinlaboratorium A process and an agent for detection of gene structures in humans having a great tendency to develop iddm

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Human Immunology, vol. 21, 1988, Am. Soc. for Histocompatability and Immunogenetics (US) G.T. Horn et al.: "Sequence analysis of HLA class II genes from insulin-dependent diabetic individuals", pages 249-263 *
Human Immunology, vol. 22, 1988, Am. Soc. for Histocompatability and Immunogenetics (US) S.J. Scharf et al.: "Sequence analysis of the HLA-DR beta and HLA-DQ beta loci from three Pemphigus vulgaris patients" pages 61-69 *
Immunogetics, vol. 24, 1986 Springer-Verlag (DE) B. Owerbach et al.: "Characterization of three HLA-DR beta genes isolated from an HLA-DR 3/4 insulin-dependent diabetic patient", pages 41-46 *
Journal of Clinical Investigation, vol. 79, April 1987 (US) B. Michelsen et al.: "Molecular cloning of a polymorphic DNA endonuclease fragment associates insulin-dependent diabetes mellitus with HLA-dq" pages 1144-1152 *
Proceedings of the National Academy of Sciences of the USA, vol. 85, May 1988 (Washington, DC, US) S.J. Scharf et al.: "HLA class II allelic variation and susceptibility to Pemphigus vulgaris" pages 3504-3508 *
Science, vol. 239, no. 4843, 26 February 1988 (Washington, DC, US) A.A. Sinha et al.: "A newly characterized HLA DQ beta allele associated with Pemphigus vulgaris", pages 1026-1029 *

Also Published As

Publication number Publication date
ATE106454T1 (en) 1994-06-15
JPH03501926A (en) 1991-05-09
CA1339098C (en) 1997-07-29
DE3889927T2 (en) 1994-11-03
EP0439458B1 (en) 1994-06-01
DE3889927D1 (en) 1994-07-07
US5665548A (en) 1997-09-09
EP0439458A1 (en) 1991-08-07
JP2877165B2 (en) 1999-03-31
WO1989004875A2 (en) 1989-06-01
US6194561B1 (en) 2001-02-27

Similar Documents

Publication Publication Date Title
WO1989004875A3 (en) Characterization and detection of sequences associated with autoimmune diseases
Jacobs et al. Insulin receptor: covalent labeling and identification of subunits.
Ambler et al. The amino acid sequence of cytochromes c-551 from three species of Pseudomonas
Fehlmann et al. Molecular association between major histocompatibility complex class I antigens and insulin receptors in mouse liver membranes.
EP0340109A3 (en) Anti-t-cell receptor determinants as autoimmune disease treatment
DE60026332D1 (en) DIAGNOSIS OF DOMESTIC SPRUE / CELIAC DISEASE WITH THE HELP OF GLIADINE PITOPENES
NO20001668D0 (en) Use of a DNA fragment, as well as complementary chains, derivatives and parts thereof
ES2072928T3 (en) ANTIGENS OF CELLS FROM PANCREATIC ISLANDS OBTAINED BY MOLECULAR CLONING.
Silver et al. Chemical characterization of murine Ia alloantigens determined by the iE/iC subregions of the H-2 complex.
KR970706306A (en) Peptides and pharmaceutical compositions comprising them
EP0177814A3 (en) Peptide antibodies and their use in detecting oncogene products
WO1996021020A3 (en) Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
Chapman et al. Complete amino acid sequence of the major early embryonic beta-like globin in chickens.
Martin et al. Carrier‐reactive hapten‐specific cytotoxic T lymphocyte clones originate from a highly preselected T cell repertoire: implications for chemical‐induced self‐reactivity
CA2109961A1 (en) Peptides for use in induction of t cell activation against hiv-1
EP0378929A3 (en) Membrane proteins and peptides of haemophilus influenzae type b
Martinko et al. Primary structure of murine major histocompatibility complex alloantigens: completion of the sequence of the amino-terminal 284 residues of H-2Kb
ZA902831B (en) Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by p.falciparum at the sporozoite stage and in the hepatocytes
CA1101842A (en) THYMOSIN .alpha.1
Uehara et al. Primary structure of murine major histocompatibility alloantigens: amino acid sequence of the cyanogen bromide fragment Ia (positions 139-228) from the H-2Kb molecule
EP0482598A2 (en) Peptide analog of human TSH receptor affective against autoimmune hyperthyroidism
CA2351722A1 (en) Mast cell-specific signal transducer and cdna thereof
AU706774B2 (en) Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (IDDM)
De Simone et al. Single-step purification of class 5 outer membrane protein from Neisseria meningitidis using preparative electrophoresis
KR970042596A (en) Human mucin MUC8

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): DK FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): DK FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989901373

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989901373

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1989901373

Country of ref document: EP